Sensitivity analyses
One-way showed that the probability of hospitalization has the highest
impact on the outcome, but MS was the dominant strategy in all range of
probabilities analyzed. The results of PSA are graphically represented
in the cost-effectiveness plane, figure 3 . 53.82% of
simulations were graphed in quadrant 2 (lower cost, high QALYs), and
45.97% in quadrant 1 of this plane (high cost, high QALYs). The 95% CI
for the cost per patient treated with FeNO-SC, and with SC were US$
1331 to 1335 and US$ 1449 to 1454. The 95% CI for QALYs per patient
was 0.93 to 0.94 and 0.91 to 0.92 respectively. The net monetary
benefits of FeNO-SC was higher than SC (US$ 16591 vs US$ 16885). The
expected net benefit with perfect information US$ 16885.9 and the
expected value of perfect information were: US$ 0.074. The
Cost-effectiveness acceptability curve shows that the probability that
FeNO-SC provides a more cost-effective use of resources compared with
standard therapy exceeds 99% for all willingness to pay thresholds. The
population expected value of perfect information (EVPIP) for the
threshold of US$ 20 was US$ 1030015.